This sounds unlikely to be true, given that getting the vaccine increases your risk of myocarditis (i.e. there's some effect on the heart muscle). Or maybe there's just some (small) percentage of cases where the spike proteins escape into the bloodstream.
Given the two dozen or so known causes of myocarditis, the vaccine does not stand out here. The risks of complications from the virus do stand out, in stark contrast.
Of course, and I'm not debating vaccine vs virus here (I've had both, myself), but even a single case of myocarditis (if we can conclusively prove that it comes from the vaccine... in reality, we can at most statistically suspect vaccine causes it) disproves the idea that "spike protein doesn't enter the bloodstream".
The theory behind "it doesn't cross" was that the modification to the spike "anchored" it to the inside of the cell, and the cell only presenting "the pointy end" (i.e. the relevant dangerous ACE2 binding domain) to the immune system, close to lymph node near the IM injection point.
Where I got my doubts about the "doesn't cross" claim, at least concerning Pfizer, which I researched :
- The identification of the spike, its in-vitro re-engineering, the formulation of a vaccine recepy took approximately two and a half months, from early Feb., 2020 to Apr. 27th, 2020. They started animal testing (60 mice, 12 monkeys) and on human volunteer (21) in parallel. It ended on Jul. 27th, '20.
- According to CT doc and FT docs, and publications, no study of biodistribution, on the theory that intra-musculary jab doesn't spread... Even though the spike protein was studied in the past (IIRC 'twas even patented around 2012 !), I didn't find any publication related to it saying it didn't cross such barriers, quite the contrary.
- They started the 40K volunteers CT right after, because of the reported absence of unwanted effects on the 20 first volunteers. Reportedly no change in formulation. Still no study.
- They started mass manufacturing during the second half of october, still no change in formulation, still no study.
The only indication of such a study was started was in the famed re-authorization letter a month ago, about them doing it now.
How and why is that even possible ? BionTech team is perfect on their first try at making a vaccine, as opposed a tailored gene therapy ? Really ?
Also :
- How do they prevent a cell presenting an anchored spike to clump with another cell with an ACE2
- Where is the study of the quality of that anchoring (i.e. what percentage of spikes don't anchor ?)
